Is twice‑daily dosing of mirtazapine appropriate for a patient with end‑stage renal disease?

Mirtazapine Dosing in ESRD: Once-Daily Administration is Standard

For patients with end-stage renal disease, mirtazapine should be administered once daily (not twice daily), with a dosage reduction from the standard dose due to decreased drug clearance in renal impairment. 1

FDA-Approved Dosing Regimen

• The FDA-approved dosing for mirtazapine is once daily, preferably in the evening prior to sleep, with a recommended starting dose of 15 mg that can be increased up to a maximum of 45 mg per day 1
• Mirtazapine's elimination half-life ranges from 20 to 40 hours, which supports once-daily dosing and allows steady-state to be reached in 4 to 6 days 2, 3
• There is no FDA indication or rationale for twice-daily (BID) dosing of mirtazapine in any patient population 1

Critical Dosing Adjustments for ESRD

• Severe renal impairment causes a 50% decrease in mirtazapine clearance, necessitating dosage reduction in ESRD patients 1, 2
• The FDA label explicitly states that "dosage decrease may be necessary when administering mirtazapine tablets to patients with moderate to severe renal or hepatic impairment" 1
• Mirtazapine is substantially excreted by the kidney (75%), and the risk of decreased clearance is greater in patients with impaired renal function 1

Practical Dosing Algorithm for ESRD

Start with 7.5 mg once daily in the evening (half of the standard 15 mg starting dose) given the 50% reduction in clearance 1, 2

• If tolerated after 1-2 weeks, may increase to 15 mg once daily in the evening 1
• Maximum dose should generally not exceed 30 mg daily (rather than the standard 45 mg maximum) due to reduced clearance 1
• Maintain once-daily evening dosing throughout treatment to optimize the drug's sedative effects and 20-40 hour half-life 1, 2, 3

Why BID Dosing is Not Appropriate

• The pharmacokinetic profile of mirtazapine does not support divided dosing: peak plasma concentrations occur within 2-3 hours, with an elimination half-life of 20-40 hours 2, 3
• Splitting the dose would not improve efficacy and could increase daytime sedation, which is already a concern in ESRD patients 1
• All clinical trials establishing mirtazapine's efficacy used once-daily dosing regimens 3, 4

Additional Safety Considerations in ESRD

• Monitor closely for over-sedation and confusion, as elderly patients and those with renal impairment are at higher risk 1
• ESRD patients may be at greater risk of hyponatremia with mirtazapine use 1
• The drug may provide beneficial effects on multiple ESRD-related symptoms including nausea, insomnia, pruritus, anxiety, and poor appetite, potentially reducing polypharmacy 5
• Recent comparative safety data in CKD patients showed mirtazapine was associated with lower upper gastrointestinal bleeding compared to SSRIs, though mortality was slightly higher 6

Common Pitfall to Avoid

Do not use standard dosing (15-45 mg) without reduction in ESRD patients, as plasma mirtazapine levels will be significantly elevated due to 50% reduction in clearance, increasing risk of adverse effects including excessive sedation 1, 2